Immunosuppression in renal transplantation: some aspects for the modern era

Transplantation Reviews

Volumn 22, Issue 4, 2008, Pages 241-251

  Chadban, Steven ^a   Morris, Randall ^b   Hirsch, Hans H ^c   Bunnapradist, Suphamai ^d   Arns, Wolfgang ^e   Budde, Klemens ^f  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AEB 071; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTETIC ACID; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; POLYOMA VIRUS; PROTEINURIA; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; VIREMIA; VIRUS INFECTION; VIRUS LOAD;

EID: 51749121765     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2008.05.003     Document Type: Article

References (79)

1. Kahan B.D. Cyclosporine. N Engl J Med 321 (1989) 1725-1738
2. Calne R. Cyclosporine as a milestone in transplantation. Transplant Proc 36 Suppl 2 (2004) 13S-15S
3. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405-2409
4. Webster A.C., Lee V.W., Chapman J.R., et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234-1248
5. Shapiro R., Young J.B., Milford E.L., et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5 (2005) 874-886
6. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378-383
7. McDonald S., Russ G., Campbell S., et al., on behalf of ANZDATA. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 7 (2007) 1201-1208
8. Jamil B., Nicholls K., Becker G.J., et al. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 68 (1999) 1597-1603
9. Kasiske B., Snyder J.J., Gilbertson D., et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 (2003) 178-185
10. Cosio F.G., Pesavento T.E., Kim S., et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62 (2002) 1440-1446
11. Hjelmesaeth J., Hartmann A., Leivestad T., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69 (2006) 588-595
12. Cosio F.G., Kudva Y., van der Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67 (2005) 2415-2421
13. Cole E.H., Johnston O., Rose C., et al. PTDM and acute rejection are associated with a similar risk for graft loss. Am J Transplant 7 Suppl 2 (2007) [Abstract 150]
14. Kaplan B., Schold J.D., and Meier-Kreische H.U. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 14 (2003) 2980-2984
15. Bunnapradist S., Peng A., Fukami S., et al. Renal allograft outcomes according to initial immunosuppressive regimen: a five year follow-up of OPTN database. Am J Transplant 5 Suppl 11 (2005) 251
16. Woodward R.S., Kutinova A., Schnitzler M.A., et al. Renal graft survival and calcineurin inhibitor. Transplantation 80 (2005) 629-633
17. Habib A.N., Smith L., Barenbaum L.L., et al. The role of maintenance immunosuppressive regimen in long term kidney transplant outcome. Am J Transplant 5 Suppl 11 (2005) 465
18. Irish W., Sherrill B., Brennan D.C., et al. Three year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple drug regimen. Transplantation 76 (2003) 1686
19. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3 (2003) 590-598
20. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 (2007) 1506-1514
21. Webster A.C., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331 (2005) 810
22. Hirsch H.H., Knowles W., Dikenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347 (2002) 488-496
23. Hirsch H.H., Brennan D.C., Drachenberg C.B., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79 (2005) 1277-1286
24. Hirsch H.H., Drachenberg C., Ramos E., et al. BK viremia level strongly correlates with the extent/pattern of viral nephropathy (BKPVN): implications for a diagnostic cut-off value. Transplantation 82 1 Suppl 3 WTC Abstracts (2006) 460
25. Brennan D.C., Agha I., Bohl D.L., et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5 (2005) 582-594
26. Hirsch H.H., Friman S., Wiecek A., et al. Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation. Am J Transplant 7 Suppl 2 (2007) [Abstract 14]
27. Williams J.W., Javaid B., Kadambi P.V., et al. Leflunomide for polyomavirus type BV nephropathy. N Engl J Med 352 (2005) 1157-1158
28. Rinaldo C.H., and Hirsch H.H. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 5 (2007) 105-115
29. Tierce J.C., Porterfield-Baxa J., Petrilla A.A., et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 19 (2005) 779-784
30. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381-2386
31. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200-205
32. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102-107
33. Hardinger K., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17 (2004) 609-616
34. Legorreta A.P., Robinson M., Gilmore A.S., et al. Gastrointestinal event associated dose reduction and discontinuation of renal transplant patients receiving MMF. Transplantation 82 Suppl 3 WTC Abstracts (2006) 485
35. Arns W., Bruer S., Choudhury S., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19 (2005) 199-206
36. Kiberd B.A., Lawen J., Fraser A.D., et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 4 (2004) 1079-1083
37. Salvadori M., Holzer H., de Mattos A., et al., on behalf of the ERLB301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231-236
38. Salvadori M., Holzer H., Civati G., et al., on behalf of the ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clinical Nephrol 66 (2006) 112-119
39. Budde K., Curtis J., Knoll G., et al., on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237-243
40. Budde K., Knoll G., Curtis J., and on behalf of the ERL B302 Study Group. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, Myfortic). Clin Nephrol 66 (2006) 103-111
41. Revicki D.A., Zodet M.W., Joshua-Gotlib S., et al. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual Life Outcomes 1 (2003) 73
42. Gwilt P.R., Nahhas R.R., and Tracewell W.G. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 20 (1991) 477-490
43. Pietruck F., Budde K., Salvadori M., et al. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clin Transplant 21 (2007) 117-125
44. Budde K., Glander P., Krämer B.K., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (2007) 417-424
45. Takahashi K., Ochiai T., Uchida K., et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant Proc 27 (1995) 1421-1424
46. Nicholls A.J. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 31 (1998) 329-333
47. Oellerich M., Shipkova M., Schütz E., et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 22 (2000) 20-26
48. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261-266
49. Hale M.D., Nicholls A.J., Bullingham R.E.S., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64 (1998) 672-683
50. Budde K., Arns W., Grandaliano G., et al. Rationale, design and statistical analysis of a prospective randomized trial comparing initially intensified vs standard dose regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. 13th Congress of the European Society for Organ Transplantation, 28 September - 3 October (2007) [Abstract 637]
51. Budde K., Arns W., Glander P., et al. Intensified dosing regimen of EC-MPS leads to higher MPA-AUC at day 3 post-transplant in de novo renal transplant patients. Preliminary results of the Pharmacokinetic and Safety of the optimyze trial. Am J Transplant 7 Suppl 2 (2007) [Abstract 1723]
52. ANZDATA Registry Report 2004. Eds. Macdonald S, Excell L. Australia and New Zealand Dialysis and Transplantation Registry. Adelaide, Australia. Available at: www.anzdata.org. Accessed September 26, 2007.
53. Pascual M., Theruvath T., Kawai T., et al. Strategies to improve long-term outcomes after renal transplantation. N Eng J Med 346 (2002) 580-590
54. Nankivell B.J., Borrows R.J., Fung C.L.S., et al. The natural history of chronic allograft nephropathy. N Eng J Med 349 (2003) 2326-2333
55. Chapman J.R., O'Connell P.J., and Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 16 (2005) 3015-3026
56. Nankivell B.J., Borrows R.J., Fung C.L.S., et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004) 557-565
57. Nankivell B.J., Borrows R.J., Fung C.L.S., et al. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 78 (2004) 461-468
58. Solez K., Vincenti F., and Filo R.S. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66 (1998) 1736-1740
59. Oppenheimer F., Aljama P., Asensio Peinado C., et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 19 Suppl 3 (2004) iii11-iii15
60. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Inter Med 130 (1999) 461-470
61. Sijpkens Y.W.J., Zwinderman A.H., Mallat M.J.K., et al. Intercept and slope analysis of risk factors in chronic renal allograft nephropathy. Graft 5 (2002) 108-113
62. Rush D., Nickerson P., Gough J., et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 9 (1998) 2129-2134
63. Bestard O., Cruzado J.M., and Grinyó J.M. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 37 (2005) 3729-3732
64. Arns W., Citterio F., and Campistol J.M. "Old-for-old"-new strategies for renal transplantation. Nephrol Dial Transplant 22 (2007) 336-341
65. Jardine A.G. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 18 (2005) 379-384
66. Arbogast H., Hückelheim H., Schneeberger H., et al. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial. Clin Transplant 19 (2005) 309-315
67. Diekmann F., Campistol J.M., Saval N., et al. Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation. Transplantation 84 (2007) 429-432
68. Pohanka E. Conversion to everolimus in maintenance patients-current clinical strategies. Nephrol Dial Transplant 21 Suppl 3 (2006) iii24-iii29
69. Racusen L. Renal allograft histopathology in protocol biopsies obtained before conversion from calcineurin inhibitor (CNI)- to sirolimus (SRL)-based immunosuppression: a report from the CONVERT study. Transplantation 82 Suppl 3 WTC Abstracts (2006) 413
70. Arns W.W., Glander P., Schuhmann R., et al. Conversion from tacrolimus to everolimus does not influence the pharmacokinetic but increases pharmacodynamic response of mycophenolate sodium in renal transplant patients. Transplantation 82 Suppl 3 WTC Abstracts (2006) 488
71. Budde K., Glander P., Schuhmann R., et al. Conversion from cyclosporine to everolimus leads to better renal function and to profound changes in everolimus and mycophenolate metabolism. Transplantation 82 Suppl 3 WTC Abstracts (2006) 999
72. Ruiz J.C., Sanchez-Fructuoso A., Rodrigo E., et al. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. Transplant Proc 38 (2006) 2424-2426
73. Holdaas H., Pfeffer P., Bentdal Ø., and Midtvedt K. Conversion from cyclosporine to everolimus at week 7 after renal transplantation is safe and improves renal function. Am J Transplant 7 Suppl 2 (2007) [Abstract 1709]
74. Flechner S.M., Kobashigawa J., and Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22 (2008) 1-15
75. Wali R.K., Mohanlal V., Ramos E., et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 7 (2007) 1572-1583
76. Weber T., Abendroth D., and Schelzig H. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. Transpl Int 18 (2005) 151-156
77. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517-2523
78. Tomlanovich S.J., and Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol 2 (2007) 198-199
79. Pascual J., Boletis I.N., and Campistol J.M. Everolimus (Certican) in renal transplantation: a review of clinical data, current usage, and future directions. Transplant Reviews 20 (2006) 1-18